Identification | |
---|---|
Name | Doxapram |
Accession Number | DB00561 (APRD00935) |
Type | small molecule |
Description | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) |
Structure |
|
Categories (*) | |
Molecular Weight | 378.5072 |
Groups | approved |
Monoisotopic Weight | 378.230728214 |
Pharmacology | |
Indication | For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. |
Mechanism of action | Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels. |
Absorption | Not Available |
Protein binding | Not Available |
Biotransformation | Not Available |
Route of elimination | Not Available |
Toxicity | Intravenous LD50 values in the mouse and rat were approximately 75 mg/kg and in the cat and dog were 40 to 80 mg/kg. Symptoms of overdosage are extensions of the pharmacologic effects of the drug. Excessive pressor effect, tachycardia, skeletal muscle hyperactivity, and enhanced deep tendon reflexes may be early signs of overdosage. |
Affected organisms |
|
Interactions | |
Drug Interactions | Not Available |
Food Interactions | Not Available |
Potassium channel subfamily K member 3 | |
---|---|
Name | Potassium channel subfamily K member 3 |
Gene Name | KCNK3 |
Pharmacological action | yes |
Actions | inhibitor |
References |
|
DTHybrid score | 0.8345 |
Potassium channel subfamily K member 9 | |
Name | Potassium channel subfamily K member 9 |
Gene Name | KCNK9 |
Pharmacological action | yes |
Actions | inhibitor |
References |
|
DTHybrid score | 0.8345 |